Evidence map›Paper›PMID 40636310›Full record

ArticleAdvanced pharmaceutical bulletin2025

Preparation and Anti-cancer Evaluation of Methotrexate-loaded Inositol-6 Phosphate Cross-linked Chitosan Nanoparticles on Breast Cancer.

Masoud Farshbaf, Nasrin Gobakhlou, Muhammad Sarfraz, Javid Shahbazi-Mojarrad, Mohammad Feyzizadeh, Hamed Hamishehkar, Parvin Zakeri-Milani, Hadi Valizadeh

Abstract read
In one paragraph

Article in Advanced pharmaceutical bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Masoud FarshbafDepartment of Medical Nanotechnology, Faculty of Advanced Medical Science, Tabriz University of Medical Science, Tabriz, Iran.ORCID https://orcid.org/0000-0003-4260-7380
Nasrin GobakhlouDepartment of Medical Nanotechnology, Faculty of Advanced Medical Science, Tabriz University of Medical Science, Tabriz, Iran.
Muhammad SarfrazCollege of Pharmacy, Al Ain University, Al Ain 64141, United Arab Emirates.
Javid Shahbazi-MojarradDrug Applied Research Center, Faculty of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran.
Mohammad FeyzizadehStudent Research Committee, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-0400-1276
Hamed HamishehkarDrug Applied Research Center, Faculty of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran.
Parvin Zakeri-MilaniLiver and Gastrointestinal Diseases Research Center, Faculty of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran.ORCID https://orcid.org/0000-0003-3243-587X
Hadi ValizadehDrug Applied Research Center, Faculty of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran.ORCID https://orcid.org/0000-0003-4157-6279

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Chitosan nanoparticles (CNs) have directed considerable research efforts towards developing biocompatible, biodegradable, inexpensive and efficient particulate drug delivery systems. Methods: In the present investigation, we utilized green and safe inositol hexaphosphate (InsP6) as a physical cross-linker to obtain CNs ( Results: Compared to Conclusion: Consequently, InsP6 can be presented as an accessible and cost-effective member of physical cross-linkers to prepare efficient CNs as drug delivery systems.

Indexed as

Breast cancerChitosanInositol hexaphosphateMethotrexate

Identifiers

PMID40636310
PMCPMC12235370

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.